Home › Burkitt-lymfoom › Michigan

Burkitt-lymfoom klinische studies in Michigan

10 studies voor Burkitt-lymfoom zoeken deelnemers op locaties in Michigan.

Steden in Michigan

Officiële studietekst (Engels)

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

C S Mott Children's Hospital, Ann Arbor
Children's Hospital of Michigan, Detroit
Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
en nog 1

RekruterenFase 2

366 Days – 46 Years · Alle geslachten · Bijgewerkt 2 okt. 2026 · NCT06124157

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
Trinity Health Medical Center - Brighton, Brighton
en nog 22

RekruterenFase 3

Leeftijden 18 tot 39 · Alle geslachten · Bijgewerkt 2 okt. 2026 · NCT03150693

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
Trinity Health Medical Center - Brighton, Brighton
en nog 20

RekruterenFase 2

Leeftijden 18 en ouder · Alle geslachten · Bijgewerkt 29 sep. 2026 · NCT03739814

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

C S Mott Children's Hospital, Ann Arbor
Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
Bronson Methodist Hospital, Kalamazoo

RekruterenFase 2

365 Days · Alle geslachten · Bijgewerkt 25 sep. 2026 · NCT06317662

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Corewell Health ( Site 1001), Grand Rapids

RekruterenFase 1/2

6 Months – 25 Years · Alle geslachten · Bijgewerkt 17 sep. 2026 · NCT06395103

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

C S Mott Children's Hospital, Ann Arbor
Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
Bronson Methodist Hospital, Kalamazoo
en nog 1

RekruterenFase 2

Leeftijden 1 tot 30 · Alle geslachten · Bijgewerkt 1 sep. 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

C S Mott Children's Hospital, Ann Arbor
Children's Hospital of Michigan, Detroit
Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
en nog 2

RekruterenFase 3

365 Days – 25 Years · Alle geslachten · Bijgewerkt 25 aug. 2026 · NCT03959085

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

C.S. Mott University of Michigan, Ann Arbor

RekruterenFase 2

Leeftijden 7 tot 25 · Alle geslachten · Bijgewerkt 19 aug. 2026 · NCT05082519

Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma

University of Michigan Rogel Cancer Center, Ann Arbor

RekruterenFase 1

Leeftijden 18 en ouder · Alle geslachten · Bijgewerkt 16 jul. 2026 · NCT07532525

The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids

RekruterenFase 2

Leeftijden 1 tot 25 · Alle geslachten · Bijgewerkt 4 mei 2025 · NCT03509961

Van ClinicalTrials.gov, gegevens opgehaald op 5 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.